| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGFR1OP2 |
| Uniprot No | Q9NVK5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-253aa |
| 氨基酸序列 | MSCTIEKALADAKALVERLRDHDDAAESLIEQTTALNKRVEAMKQYQEEIQELNEVARHRPRSTLVMGIQQENRQIRELQQENKELRTSLEEHQSALELIMSKYREQMFRLLMASKKDDPGIIMKLKEQHSKIDMVHRNKSEGFFLDASRHILEAPQHGLERRHLEANQNELQAHVDQITEMAAVMRKAIEIDEQQGCKEQERIFQLEQENKGLREILQITRESFLNLRKDDASESTSLSALVTNSDLSLRKS |
| 分子量 | 55.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为关于重组人FGFR1OP2蛋白的参考文献列表(注：文献为虚拟示例，实际检索需通过数据库验证)：
---
1. **文献名称**: *Expression and functional characterization of recombinant human FGFR1OP2 in hepatocellular carcinoma*
**作者**: Li, X., et al.
**摘要**: 本研究通过大肠杆菌系统成功表达了重组人FGFR1OP2蛋白，并发现其在肝癌细胞中通过调控MAPK信号通路抑制肿瘤增殖，为肝癌靶向治疗提供了潜在分子靶点。
2. **文献名称**: *Structural insights into FGFR1OP2-mediated protein-protein interactions in glioblastoma*
**作者**: Smith, J. R., et al.
**摘要**: 利用重组FGFR1OP2蛋白进行X射线晶体学研究，揭示了其与FGFR1胞内结构域的相互作用界面，解释了FGFR1OP2在胶质母细胞瘤中异常调控受体活性的分子机制。
3. **文献名称**: *FGFR1OP2 as a novel regulator of mitochondrial dynamics: Purification and functional analysis*
**作者**: Wang, Y., et al.
**摘要**: 通过哺乳动物细胞系(HEK293)表达并纯化重组FGFR1OP2蛋白，发现其通过结合线粒体分裂蛋白Drp1.调控线粒体形态与细胞凋亡过程，提示在神经退行性疾病中的潜在作用。
---
**注意事项**：
- 实际研究中建议通过PubMed、Web of Science等数据库检索真实文献;
- 若主题较新或研究较少，可扩展关键词如“FGFR1 oncogene partner 2”或结合疾病名称(如肿瘤、阿尔茨海默病)进行检索;
- 部分早期研究可能未直接涉及重组蛋白，需筛选标题/摘要中的关键词。
Recombinant human FGFR1OP2 (Fibroblast Growth Factor Receptor 1 Oncogene Partner 2) protein is a engineered version of a naturally occurring protein involved in diverse cellular processes. FGFR1OP2. also known as FOP2. was initially identified as a fusion partner of the FGFR1 kinase in myeloproliferative disorders. It encodes a nucleocytoplasmic shuttling protein with a conserved N-terminal leucine-rich repeat (LRR) domain and a C-terminal fibronectin type III (FN3) domain, suggesting roles in protein-protein interactions and cellular signaling. Though its precise biological function remains under investigation, FGFR1OP2 is implicated in regulating cytoskeletal dynamics, cell cycle progression, and possibly influencing transcriptional activities through nuclear localization. Dysregulation of FGFR1OP2 has been linked to cancers, including leukemia and solid tumors, where altered expression or fusion events may contribute to oncogenic pathways. Recombinant FGFR1OP2 is typically produced in bacterial or mammalian expression systems for functional studies. Researchers use it to explore interactions with binding partners (e.g., FGFR1. centrosomal proteins), structural characterization, and mechanisms underlying its involvement in diseases. Current studies focus on clarifying its physiological roles and potential as a therapeutic target, particularly in cancers with FGFR1OP2-related aberrations. Challenges include elucidating context-dependent functions and reconciling conflicting data from different experimental models. Its recombinant form remains a critical tool for unraveling molecular pathways in both normal and pathological states. (295 words)
×
